Company intelligence / Profile preview
Jiangsu Maidu Pharmaceutical Research and Development
Taizhou, Jiangsu, China
- Ownership
- Private
- Employees
- ~900
- Development stage
- Other
01
Overview
Jiangsu Maidu Pharmaceutical Research and Development, a subsidiary of Zelgen, is primarily focused on developing small molecule oncology therapies. Its lead program, sutetinib maleate, has demonstrated clinical activity in Phase 2 trials for non-small cell lung cancer patients with rare EGFR mutations. Its dual BTK/EGFR inhibitor, kenaitinib, is currently in Phase 1 clinical testing for B-cell lymphomas.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gensun BiopharmaAlphamab Oncology
Beyond the preview
Go deeper on Jiangsu Maidu Pharmaceutical Research and Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Maidu Pharmaceutical Research and Development.